AtuFECT01
AtuFECT01 is a cationic lipid component. AtuFECT01 is used to construct AtuPLEX/Atu027 Lipid nanoparticles. AtuFECT01 improves cellular uptake and endosomal escape of siRNA in AtuFECT01-based lipoplexes. Formulation of AtuFECT01 with Tie2 siRNA into lipoplexes reduces Tie2 expression in mouse lung.
For research use only. We do not sell to patients.
- CAS No.: 869094-19-9
- Formula: C43H90Cl3N7O2
- Molecular Weight:843.58
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vitro
AtuFECT01-based siRNA-lipoplexes (1-50 nM; 48 h) inhibit PKN3 protein expression in HeLa cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
DACC/AtuFECT01 lipoplexes (0.75-3 mg siRNA/kg; intravenous bolus; single or once daily; 3 consecutive days) mediate dose-dependent, lung endothelial-specific knockdown of Tie-2, CD31, VEGFR2, VE-Cadherin, and BMPR-2 in C57Bl/6j healthy mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Hsd:NMRI-nu/nu nude (male, 9 weeks)[2]
-
Dosage:1.88 mg/kg siRNA and 14.5 mg/kg lipid
-
Administration:i.v. via tail vein; once daily; four consecutive days
-
Result:Reduced Tie2 mRNA in lung, heart, and liver after siRNA^Tie2-lipoplex administration.
Reduced CD31 mRNA in lung, heart, and liver after siRNA^CD31-lipoplex administration.
Reduced Tie2 mRNA more prominently than CD31 mRNA in liver.
Inhibited both target genes similarly in lung and heart.
Reduced Tie2 protein in all three analyzed organs after siRNA^Tie2-lipoplex administration.
Reduced CD31 protein in lung and heart after siRNA^CD31-lipoplex administration.
Reduced serum soluble Tie2 on day 5 in siRNA^Tie2-lipoplex-administered mice compared with sucrose, siRNA^PTEN, and siRNA^CD31 control cohorts.
Observed no suppression of endothelial gene expression in kidney and spleen.
Chemical Information
-
CAS No. 869094-19-9
-
Molecular Weight 843.58
-
Formula C43H90Cl3N7O2
-
SMILES
N=C(N)NCCC[C@H](N)C(NC[C@H](N)C(N(CCCCCCCCCCCCCCCC)CCCCCCCC/C=C\CCCCCCCC)=O)=O.Cl.Cl.Cl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
RNA interference technology
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing gene transcription or activating RNA degradation. This mechanism was discovered in plants in 1998 by Andrew Fire and Craig Mello. Today, this phenomenon can be observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals.
Purity & Documentation
References
[1]. Miller AD, et al. Delivery of RNAi therapeutics: work in progress. Expert review of medical devices. 2013 Nov;10(6):781-811. [Content Brief]
[4]. Hattori Y, et al. Effect of cationic lipid in cationic liposomes on siRNA delivery into the lung by intravenous injection of cationic lipoplex. Journal of drug targeting. 2019 Feb;27(2):217-227. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
AtuFECT01 Related Classifications
HY-112765 Related Classifications
Powered by Bioz